Form 4: Broadwood Partners Acquires Significant Stake in Lineage Cell Therapeutics Following Shareholder Approval

Broadwood Partners, L.P. has acquired 7,894,737 common shares and warrants in Lineage Cell Therapeutics for $6 million, following shareholder approval.

Summary

• Broadwood Partners, L.P. purchased 7,894,737 common shares of Lineage Cell Therapeutics at $0.76 per share, along with an equal number of common share purchase warrants.
• The total transaction was valued at $6 million.
• The purchase was made through a registered direct offering.
• The closing of the transaction was contingent on shareholder approval, which was obtained on January 27, 2025.
• The warrants are exercisable for one common share at a price of $0.91.
• The warrants expire on the earlier of May 21, 2028, or 90 days after the public disclosure of the intent to advance OpRegen into a multi-center phase 2 or 3 clinical trial with a control arm, or if such disclosure occurs before May 21, 2025, then 90 days after May 21, 2025.
• Broadwood Partners now directly owns 49,560,992 common shares.
• Neal C. Bradsher, as President of Broadwood Capital, Inc., may be deemed to beneficially own the securities held by Broadwood Partners.

Sentiment

Score: 7

Explanation: The document indicates a significant investment in the company, which is generally positive. However, the warrants introduce some uncertainty and potential dilution.

Positives

• The transaction provides Lineage Cell Therapeutics with $6 million in funding.
• Broadwood Partners' significant investment demonstrates confidence in Lineage Cell Therapeutics.
• Shareholder approval was obtained, indicating support for the transaction.

Risks

• The warrants' expiration is tied to the progress of the OpRegen clinical trial, which introduces uncertainty.
• The exercise of the warrants could dilute existing shareholders if exercised.

Future Outlook

The warrants' value is contingent on the progress of the OpRegen clinical trial and the share price of Lineage Cell Therapeutics.

Management Comments

• Neal C. Bradsher, President of Broadwood Capital, Inc., signed the Form 4 on behalf of Broadwood Partners, L.P. and Broadwood Capital, Inc.

Industry Context

This transaction reflects continued investment in the biotechnology sector, particularly in companies focused on cell therapies. It is common for investors to use warrants as part of the investment structure.

Comparison to Industry Standards

• The purchase of shares and warrants is a common structure in biotech financing, similar to deals seen with companies like Athersys and Mesoblast.
• The warrant exercise price of $0.91 is typical for such transactions, often set at a premium to the current share price.
• The warrant expiration terms tied to clinical trial progress are also common in the biotech industry, aligning investor interests with company milestones.

Stakeholder Impact

• Shareholders may experience dilution if the warrants are exercised.
• The investment provides Lineage Cell Therapeutics with capital to fund operations and research.
• The transaction could positively impact the company's share price.

Next Steps

• Lineage Cell Therapeutics will continue to develop its therapies, including OpRegen.
• Broadwood Partners may exercise their warrants in the future, depending on the company's performance and the progress of the OpRegen clinical trial.

Key Dates

Keywords

Lineage Cell Therapeutics, Broadwood Partners, common shares, warrants, shareholder approval, direct offering, OpRegen, investment